Business Wire

OR-NUSCALE-POWER

9.12.2020 21:05:08 CET | Business Wire | Press release

Share
NuScale Power Releases Updated Evaluation for 77 MWe Module Clean Hydrogen Production

NuScale Power today announced updated evaluations for the technical feasibility and economics of producing hydrogen using heat and electricity from a NuScale Power Module™ (NPM) as a result of the recent announcement that an NPM can generate an additional 25 percent more power per module for a total of 250 MWt (or 77 MWe) per module. The hydrogen study was originally conducted in 2014 with the Idaho National Laboratory and has been updated with new production and economic parameters.

The updated analysis found that with the 25 percent increase in power output of an NPM, one 250 MWt NuScale module is capable of producing 2,053 kg/hour of hydrogen, or nearly 50 metric tons per day, an increase from 1,667 kg/hour of hydrogen or 40 metric tons per day for a 200 MWt NuScale module. Moreover, as a result of the lower levelized cost of electricity from the increased power output, hydrogen produced by a NuScale high-temperature steam electrolysis (HTSE) system is forecasted to be cost competitive with high capacity factor renewable hydrogen cost estimates while also providing continuous, controlled hydrogen production.

“The ability of our NPM to now produce even more clean hydrogen, in a smaller footprint, is yet another example of how NuScale’s technology can help decarbonize various sectors of the economy while providing additional revenue streams for customers,” said Dr. José Reyes, Chief Technology Officer and Co-founder of NuScale Power. “Coupled with our proven design, unparalleled safety, and load following capabilities, this analysis further demonstrates that NuScale’s design is the gold standard in helping meet the demand for innovative solutions to challenging global energy needs.”

In the analysis, energy from a single NPM in the form of superheated steam and electricity are directly routed to a HTSE system operating at 850°C. Only 2 percent of the electrical output (~1.8 MWe) of the NPM is used to increase the process steam temperature from 300°C at the NPM outlet to 850°C for the electrolyzer. NuScale’s innovative multi-module power plant design means that a NuScale plant could produce reliable clean electricity for the grid while allocating one or more modules to economically produce hydrogen when electricity demand is low.

According to a recent report from LucidCatalyst , in order for the world to meet the Paris goals of keeping warming between 1.5–2°C, sufficient, low-cost, clean hydrogen production is needed to replace oil and gas in shipping, aviation, and industry. Over 95% of the world's hydrogen is currently produced using fossil fuels, with the most common method being steam methane reforming from natural gas. Renewables cannot produce all of this hydrogen alone, and advanced modular reactors will be required to produce enough clean hydrogen to displace the 100 million barrels of oil that are currently consumed around the world each day. Using a single NPM to produce 50 tons of hydrogen per day would avoid about 460 tons of CO2 emissions per day, or 168,000 tons of CO2 per year, as compared to producing hydrogen from natural gas. Additionally, NuScale’s ability to produce clean hydrogen is perfectly suited to assist in decarbonizing transportation, since a single NPM can produce enough hydrogen to power 38,000 fuel cell vehicles or 1,500 long-haul fuel cell trucks at average annual fuel usage rates in the United States.

​​​​​About NuScale Power

NuScale Power has developed a new modular light water reactor nuclear power plant to supply energy for electrical generation, district heating, desalination, and other process heat applications. This groundbreaking small modular reactor (SMR) design features a fully factory-fabricated NuScale Power Module™ capable of generating 77 MW of electricity using a safer, smaller, and scalable version of pressurized water reactor technology. NuScale's scalable design—a power plant can house up to four, six, or 12 individual power modules—offers the benefits of carbon-free energy and reduces the financial commitments associated with gigawatt-sized nuclear facilities. The majority investor in NuScale is Fluor Corporation, a global engineering, procurement, and construction company with a 60-year history in commercial nuclear power.

NuScale is headquartered in Portland, OR and has offices in Corvallis, OR; Rockville, MD; Charlotte, NC; Richland, WA; and London, UK. Follow us on Twitter: @NuScale_Power , Facebook: NuScale Power, LLC , LinkedIn: NuScale-Power , and Instagram: nuscale_power . Visit NuScale’s website .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release

Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit

Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse

Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig

PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye